Recombinant and plasma-purified human c1 inhibitor for the treatment of hereditary angioedema

Michael M Frank, Michael M Frank

Abstract

Background: : Agents for prophylaxis of hereditary angioedema (HAE) have been available in the United States for several decades, but their usefulness is limited by side effects and they cannot be used at all in some patients. No agents have been available in the United States to specifically treat acute attacks. HAE types I and II are associated with low functional levels of C1 inhibitor, and evidence accumulated over decades suggests that intravenous infusion of C1 inhibitor is useful for terminating angioedema attacks and for prophylaxis.

Key points: : C1 inhibitor derived from pooled human plasma has been available for decades in Europe, and 2 preparations have been recently introduced into the United States. Both have been efficacious in carefully controlled double-blind studies. One preparation, Cinryze, was approved by the U.S. Food & Drug Administration (FDA) for prophylaxis of HAE attacks in October 2008, and the second, Berinert, was approved by the FDA for treatment of acute attacks in October 2009. A third preparation, the recombinant human C1 inhibitor Rhucin, is completing clinical trials. Although not yet approved by the FDA, preliminary results made available suggest that Rhucin, too, is effective in terminating attacks of HAE.

Conclusions: : Americans will now have access to effective acute and prophylactic treatments with C1 inhibitor for hereditary angioedema.

Figures

Figure 1
Figure 1
Two plasma-derived C1 inhibitor preparations, Cinryze (A) and Berinert (C), and a recombinant protein, Rhucin (B), provide faster symptom relief for acute HAE attacks than placebo. Reprinted with permission from (A) New England Journal of Medicine,[22], (B) Pharming Group NV, (C) Journal of Allergy and Clinical Immunology[23].

References

    1. Frank MM, Gelfand JA, Atkinson J. Hereditary angioedema: The clinical syndrome and its management. Ann Intern Med. 1976;3(5):580–593. doi: 10.7326/0003-4819-84-5-580.
    1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;3(10):1027–1036. doi: 10.1056/NEJMcp0803977.
    1. Davis AE. 3rd. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;3(1):3–9. doi: 10.1016/j.clim.2004.05.007.
    1. Lundh B, Laurell A, Wetterqvist H, White T, Granerus G. A case of hereditary angioneurotic oedema, successfully treated with epsilonaminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism. Clin Exp Immunol. 1968;3(7):733–745.
    1. Nilsson I, Andersson L, Björkman SE. Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 year's clinical experience. Acta Med Scand Suppl. 1966;3:1–46.
    1. Frank M, Sergent J, Kane M, Alling D. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med. 1972;3(15):808–812. doi: 10.1056/NEJM197204132861503.
    1. Sheffer AL, austen K, Rosen F. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;3(9):452–454. doi: 10.1056/NEJM197208312870907.
    1. Gelfand JA, Sherins R, Alling D, Frank M. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;3(26):1444–1448. doi: 10.1056/NEJM197612232952602.
    1. Zurlo J, Frank M. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril. 1990;3(1):64–72.
    1. Széplaki G, Varga L, Valentin S, Kleiber M, Karádi I. et al.Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol. 2005;3(4):864–869. doi: 10.1016/j.jaci.2004.12.1130.
    1. Pickering R, Good R, Kelly J, Gewurz H. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet. 1969;3(7590):326–330.
    1. Donaldson V, Evans R. A biochemical abnormality in herediatry angioneurotic edema: Absence of serum inhibitor of C' 1-esterase. Am J Med. 1963;3:37–44. doi: 10.1016/0002-9343(63)90162-1.
    1. Rosen F, Pensky J, Donaldson V, Charache P. Hereditary angioneurotic edema: Two genetic variants. Science. 1965;3:957–958. doi: 10.1126/science.148.3672.957.
    1. Gadek J, Hosea S, Gelfand J, Santaella M, Wickerhauser M, Triantaphyllopoulos D, Frank M. Replacement therapy in hereditary angioedema: Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Eng J Med. 1980;3:542–546. doi: 10.1056/NEJM198003063021002.
    1. Agostoni A, Bergamaschini L, Martignoni G, Cicardi M, Marasini B. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy. 1980;3(5):299–301.
    1. Bork K, Witzke G. Hereditares angioneurotisches Odem. Klinik sowie erweiterte diagnostische und therapeutische Moglichkeiten [Hereditary angioneurotic edema. Clinical aspects and extended diagnostic and therapeutic possibilities] In German. Deutsche medizinische Wochenschrift. 1979;3(11):405–409. doi: 10.1055/s-0028-1103919.
    1. Waytes AT, Rosen F, Frank M. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;3:1630–1634. doi: 10.1056/NEJM199606203342503.
    1. Bork K, Barnstedt S. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;3(5):714–718. doi: 10.1001/archinte.161.5.714.
    1. Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005;3(11):1774–1784. doi: 10.1111/j.1537-2995.2005.00602.x.
    1. Koles K, van Berkel PH, Pieper F, Nuijens J, Mannesse M, Vliegenthart J, Kamerling J. N-and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology. 2004;3(1):51–64.
    1. Choi G, Soeters M, Farkas H, Varga L, Obtulowicz K. et al.Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;3(6):1028–1032. doi: 10.1111/j.1537-2995.2007.01239.x.
    1. Zuraw B, Busse P, White M, Jacobs J, Lumry W, Baker J, Craig T. et al.Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema. New England Journal of Medicine. 2010;3(6):513–522. doi: 10.1056/NEJMoa0805538.
    1. Craig T, Levy R, Wasserman R, Bewtra A, Hurewitz D. et al.Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;3(4):801–808. doi: 10.1016/j.jaci.2009.07.017.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅